scispace - formally typeset
Z

Zhen Tao

Researcher at Tianjin Medical University Cancer Institute and Hospital

Publications -  23
Citations -  839

Zhen Tao is an academic researcher from Tianjin Medical University Cancer Institute and Hospital. The author has contributed to research in topics: Tumor microenvironment & Medicine. The author has an hindex of 11, co-authored 17 publications receiving 596 citations. Previous affiliations of Zhen Tao include Thomas Jefferson University & Tianjin Medical University.

Papers
More filters
Journal ArticleDOI

Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo

TL;DR: The findings suggest that MEK inhibitor in combination with CDK4/6 inhibitor has significant anti-KRAS–mutant NSCLC activity and radiosensitizing effect in preclinical models, potentially providing a novel therapeutic strategy for patients with advanced KRAS-mutants NSCLCs.
Journal ArticleDOI

Single-Cell Transcriptome Analysis Reveals Intratumoral Heterogeneity in ccRCC, which Results in Different Clinical Outcomes.

TL;DR: This study verified that T cell exhaustion was the key factor responsible for the immunosuppressive property of ccRCC tissues, which was significantly related to poor prognosis, and found that abnormal metabolic patterns occurred not only in cancer cells, but also in tumor-infiltrating stromal cells.
Journal ArticleDOI

Let-7c blocks estrogen-activated Wnt signaling in induction of self-renewal of breast cancer stem cells

TL;DR: These findings identified a biochemical and functional link between let-7c with ERα/Wnt signaling in breast cancer stem cells and found that higher expression levels of let- 7b and let-8c were correlated with better clinical prognosis of patients with estrogen receptor (ER)α-positive breast tumor.
Journal ArticleDOI

MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1

TL;DR: The results demonstrated that overexpression of miR-497 sensitizes the resistant ovarian tumor to cisplatin treatment, and it is suggested that mi R-497 might be used as a therapeutic supplement to increase ovarian cancer treatment response to cis Platin.